Trial document




drksid header

  DRKS00016970

Trial Description

start of 1:1-Block title

Title

Serotonergic Modulation of Waiting Impulsivity- a translational study in mice and men

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

Tph2_Wl

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

http://none

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

[---]*

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Attention-Deficit Hyperactivity Disorder (ADHD) is a heterogeneous disease that frequently presents with co-occurring psychiatric disorders, e.g. conduct disorder and anxiety. By bridging the fields of basic research and clinical science, translational studies have increasingly gained importance, nurturing our understanding of the underlying mechanisms of comorbidities and exploring novel treatment perspectives. In the case of the serotonin-catalizing tryptophan hydroxylase-2 (TPH2) gene, the null mutant mice (Tph2-/-) have been discussed as candidate model for ADHD. Variants of the TPH2 gene have been associated with ADHD, increased impulsive behavior, increased aggression and altered anxiety behavior.
Derived from the combined phenotypic alterations in anxiety, impulsivity and aggression in the TPH2 KO mouse model and clinical findings, the aim of this study is to quantify these phenotypic dimensions in a clinical pediatric sample of 250 ADHD patients and typically developing children. All participants will be (a) genotyped for the TPH2 (G-703T; rs4570625) variant, (b) phenotyped for impulsivity, aggression and anxiety as suggested by the international Research Domain Criteria (RDoC) and (c) examined using the 5-choice serial reaction time task in the fMRI scanner. In a second step, the mediating and moderating interaction of the dimensional phenotypes will be characterized by clinical, behavioral and neural parameters.
Using an adapted version of the reverse phenotyping approach, this study will provide insight into the mechanisms of phenotypic complexity in comorbid disorders associated with ADHD. Broader societal, political and scientific impact may be expected from the findings in terms of developing age-adapted targeted intervention and prevention programs in ADHD.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00016970
  •   2019/04/17
  •   [---]*
  •   yes
  •   Approved
  •   2018-306-Drittmittel, Ethik-Kommission an der Medizinischen Fakultät der Heinrich-Heine-Universität Düsseldorf
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2018-114-851  (Studienregister des Universitätsklinikums Düsseldorf)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   F90 -  Hyperkinetic disorders
  •   ANXIETY AGGRESSIVENESS
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   In this cross-sectional study, 250 children and adolescents with and without ADHD are examined. A dimensional approach as suggested by the rDoC is applied.
    Using fMRI we examine the influence of anxiety and aggression on impulsivity by correlating trait anxiety and aggression with behavioral, neural and connectivity parameters of an impulsivity task. Study duration is 3 years.
  •   In this study we follow the dimensional approach as suggested by the rDoC. Therefore, patients and controls are pooled in one group. We will not perform goup comparisons.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Other
  •   Other
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Basic research/physiological study
  •   Other
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

The study, or better data acquisition of fMRI and questionnaire data will end when the calculated minimal sample size of n=250 is reached. The financial support will end in summer 2021.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

/

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Planned
  •   2019/07/01
  •   150
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   8   Years
  •   18   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

general criteria are:
IQ > 80
aged from 8-18 years

For ADHD patients:
F90 diagnosis, commorbidities are okay

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

general criteria are:
no current neurological disease
no metal body implants (Retainer, Bracelets etc.)

For healthy controls:
no current or history of neurological and psychiatric diseases, no family history of neurological and psychiatric disease

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Düsseldorf
    • Moorenstr. 5
    • 40225  Düsseldorf
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität Düsseldorf
    • Ms.  PD Dr. rer. nat.  Susanne  Neufang 
    • Bergische Landstraße 2,
    • 40629  Düsseldorf
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität Düsseldorf
    • Ms.  PD Dr. rer. nat.  Susanne  Neufang 
    • Bergische Landstraße 2,
    • 40629  Düsseldorf
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Deutsche Forschungsgemeinschaft
    • Kennedyallee 40
    • 53175  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting planned
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  •   ethical vote
  •   Studienprotokoll
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.